Optiscan Signs New Research Agreement for Breast Study
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Optiscan Imaging Limited has signed a research agreement to initiate a breast cancer imaging study in the US, aimed at generating clinical evidence for FDA submissions. The study will evaluate the performance of Optiscan's InVue™ and InForm™ devices in patients undergoing breast conserving surgery. This collaboration with Mayo Clinic seeks to validate an integrated surgical-pathology workflow and support commercial expansion in the US market. The CEO emphasized that this study is a significant milestone for generating high-quality clinical evidence and refining their technologies for surgical workflows.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Optiscan Imaging Limited on 6ix
Story so far
Earlier from Optiscan Imaging
- Head and Neck Study Progressing Ahead of Schedule
- Optiscan Launches InSpecta Device for Veterinary Medicine
- Halfway Mark Reached in Optiscan Breast Cancer Study
- Second Anniversary of Optiscan and Mayo Clinic Agreement
- Optiscan Receives $1.69m R&D Tax Refund
Later from Optiscan Imaging
- Preliminary Final Report
- Optiscan Initiates Head and Neck Cancer Study in the US
- Significant Milestone Reached in ACL Digital Pathology Study
- Optiscan Lodges U.S. FDA 510(k) Submission for InForm
- Optiscan Lodges U.S. FDA 510(k) Submission for InVue
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging